{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-014073","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.613116+00:00","generated_at":"2026-05-17T06:19:09.239336+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants","bullets":["Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.","Gross proceeds ~$2.2M; H.C. Wainwright acted as placement agent (7% fee).","Company issued new unregistered Series C (2,424,998 shares, 5-yr term) and Series D (2,424,998 shares, 18-mo term) warrants at $0.915.","New warrants exercisable only after stockholder approval; proceeds for working capital and product development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-014073","json":"https://secwatch.observer/filing/0001493152-25-014073.json","markdown":"https://secwatch.observer/filing/0001493152-25-014073.md","text":"https://secwatch.observer/filing/0001493152-25-014073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/0001493152-25-014073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:19:09.239336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af577d188d6fc534773dd7035db0db6121ca6ab2","claim":"Enveric Biosciences, Inc. issued up to 2,424,998 shares of Common Stock of warrant to certain institutional investors (the \"Holders\") for aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees.","evidence_excerpt":"(the “New Series D Warrant Shares” and, together with the New Series C Warrant Shares, the “New Warrant Shares.”) The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other offering expenses payable by the Company. The Company engaged H.C.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315225014073/0001493152-25-014073-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 2,424,998 shares of Common Stock"},{"label":"Purchaser","value":"certain institutional investors (the \"Holders\")"},{"label":"Consideration","value":"aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}